Gestoden

from Wikipedia, the free encyclopedia
Structural formula
Structure of gestodes
General
Non-proprietary name Gestoden
other names

13-ethyl-17 β -hydroxy-18,19-dinor-4,15-pregnadien-20-in-3-on

Molecular formula C 21 H 26 O 2
External identifiers / databases
CAS number 60282-87-3
EC number 262-145-8
ECHA InfoCard 100.056.478
PubChem 3033968
ChemSpider 2298532
DrugBank DB06730
Wikidata Q408289
Drug information
ATC code

G03 AA10 G03 AB06

Drug class

Progestins

properties
Molar mass 310.43 g · mol -1
Physical state

firmly

density

1.177 g cm −3

Melting point

197-198 ° C

safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances
08 - Dangerous to health

Caution

H and P phrases H: 361
P: ?
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Gestoden is a synthetic 3rd generation progestin that is used as a hormonal contraceptive for birth control.

It is a selective, strong antigonadotropic pro gestagen . The antigonadotropic effect is about three times stronger than that of levonorgestrel . It is the only progestagen that has an aldosterone antagonistic effect, which is due to its high affinity for the progesterone receptor . It also has a minimal residual androgenic effect and a weak anti-estrogenic effect. Gestoden is only available in combination with ethinylestradiol in the form of dragees, tablets and plasters.

properties

Gestodene occurs in two polymorphic crystal forms. Form II is thermodynamically stable at room temperature. At 36 ° C it transforms enantiotropically into form I. Form I then melts at 197 ° C.

Trade names

Combination preparations

Femovan (D), Minulet (D, A, CH), Minesse (A, CH), Mirelle (A, CH), Tri-Minulet (FR)

literature

  • Helmut Hofmeister, K. Annen, Henry Laurent et al .: Syntheses of gestoden. Research laboratories of Schering Aktiengesellschaft, Berlin-West / Bergkamen, Germany. Arzneimittel-Forsch / Drug-Res 36 (1986), pp. 781-783.
  • Fv Bruchhausen: Hager's handbook of pharmaceutical practice. Springer Berlin Heidelberg, 1994, ISBN 978-3-540-52688-9 , p. 341 ( limited preview in Google book search).
  • J. Spona, J. Huber: Pharmacological and endocrine profiles of gestodene. Int J Fertil 32 (1987) Suppl, 6-14, PMID 2906347 .

Individual evidence

  1. ^ Emil Eckle, Georg-Alexander Hoyer, Helmut Hofmeister, Henry Laurent, Rudolf Wiechert, Dietmar Schomburg: The crystal and molecular structure of gestodes. Liebigs Ann. Chem. (1988), 199-202, doi : 10.1002 / jlac.198819880303 .
  2. ↑ Patent EP2354150 : Process for the preparation of gestodene. Published on August 10, 2011 , applicant: Theramex, inventor: Jean-Luc Moutou, Florent Mouton, Gilles Pellegrino, Jan-Marc Dillenschneider, Jean Lafay. ‌
  3. ↑ Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of Gestodene in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), which was accessed on April 2, 2020, is reproduced from a self-classification by the distributor .
  4. ↑ Thomas Rabe , Benno Runnebaum , Stefanie Kellermeier-Wittlinger: hormone therapy. In: Thomas Rabe, Benno Runnebaum: Gynecological Endocrinology. Springer-Verlag, Berlin 1994, ISBN 3-540-57345-3 , p. 70.
  5. ^ Li-yu Wang, Liang Zhu, Zuo-liang Sha, Xian-chao Li, Yan-fei Wang, Li-bin Yang, Xiao-yu Zhao: Characterization, thermal stability, and solid-state phase transition behaviors of gestodene polymorphs and amorphous phase in J. Therm. Anal. Calorim. 127 (2017) 1533-1542, doi : 10.1007 / s10973-016-5438-2 .

Web links